HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (NASDAQ: KRBP), a clinical-stage biotherapeutics company using its proprietary DIAMOND ® artificial intelligence (AI) and data mining platform to ...
After nearly 40 years of research on how Listeria bacteria manipulate our cells and battle our immune system to cause listeriosis, Daniel Portnoy and his colleagues have discovered a way to turn the ...
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- IN8bio (INAB) (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, presented in an oral session ...
NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a ...
- Gamma-delta nsCAR platform emerging as an advanced technology for targeting hematologic and solid tumor cancers NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (INAB) (Nasdaq: INAB) a ...
(RTTNews) - IN8bio, Inc. (INAB) announced the launch of its next-generation Gamma-Delta T-cell engager or TCE platform INB-600, designed to overcome the limitations of existing Gamma-Delta TCE ...
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the ...
INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target cancer cells while sparing healthy tissue when both express the CAR-targeted antigen. CAR ...
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (NASDAQ: KRBP), a clinical-stage biotherapeutics company using its proprietary DIAMOND AI ® (artificial intelligence) and data mining platform to ...
ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment of ...
CHICAGO — Adicet Bio reported Monday that a unique, off-the-shelf therapy made from a special type of T cell induced complete remissions in patients with advanced and aggressive B-cell lymphomas, ...
The "Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. After vicennium of futuristic T cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results